Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 5Unknown 2Completed 2Active not recruiting 2Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2CNS 2Sarcoma 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Automobiles × Lymphoid × Clear all
NCT02659943 2023-04-19

T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
27 enrolled 25 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡